Overview
Founded in Liege in 2014, KiOmed Pharma develops injectable medical devices based on CM-chitosan, a biocompatible polysaccharide derivative. The company's lead product targets osteoarthritis, a condition affecting hundreds of millions of people globally and representing a major burden on healthcare systems.
CM-chitosan offers a biologically derived alternative to the synthetic hyaluronic acid injections commonly used for joint lubrication in osteoarthritis treatment. KiOmed's devices have been administered to over 35,000 patients, and the company has secured approval from the Chinese FDA (NMPA), opening access to one of the world's largest markets for this indication.
In 2025, KiOmed raised EUR 18M to support commercial scale-up across European and Asian markets. The company is part of the Liege life sciences cluster, which also includes university spin-offs from the University of Liege.
Funding & milestones
1 events found for KiOmed Pharma · 2025
Funding eventType unspecifiedDetails€18M
Reported amount €18,000,000
Source not attached to this recordDeal record
Recorded history so far. Original currencies are preserved; amounts in different currencies are not added together. Debt, grants, acquisitions and listings are separate event types. Undated events appear last.
Profile narrative
- Growth round, EUR 18M, 2025
Key people
In the news
- KiOmed Pharma était ravi de participer au gala de la Fondation Arthrose, que nous sommes fiers de soutenir depuis plusieurs années. 🎗️ Une belle soirée qui a mis à l’honneur la recherche et les chercheurs qui s’engagent au quotidien pour améliorer la prise en charge de l’arthrose. Toutes nos félicitations aux lauréats de cette édition. 👏 Un grand merci à Yves Henrotin, Celine Mathy et à toute l’équipe de la Fondation pour leur chaleureux accueil. #Arthrose #Recherche #FondationArthrose #KiOmedPharma The Osteoarthritis
- If you had to describe KioMedine in one word, what would it be?” That’s the question we asked at our latest Clinical Expert Meeting. The words differed. The message did not: they all see the potential of KioMedine for their patients. A big thank you to everyone who took part and played along. See their answers for yourself. 🙏 Dr Lucia Pelegrin, Dr Ahmet Cemil Turan, Dr Lotfi AMOURA, Dr Yasir Fayaz, Dr Maad Faisal Alsaati, Dr Özlem Taşoğlu, Dr Krik Heusdens, MD, PhD, Dr Emmanuel Fouarge, Dr Demirhan Dıraçoğlu, Dr Bohdan Ivaniv
- Thank you, Dr Suresh Sudula, for joining us in Brussels, and for these words on CM-Chitosan and the management of refractory osteoarthritis.
- Great to see the KioMedine Clinical Expert Meeting resonate beyond the room. Thank you, Dr Maad Faisal Alsaati, for sharing your real-world experience from Saudi Arabia and for being part of this international exchange.
- Last week we hosted the 4th KioMedine Clinical Expert Meeting, welcoming 126 healthcare professionals from 23 countries for two days in Brussels. The programme was built around clinicians who use KioMedine in their daily practice. They presented results from their own patients and reviewed the latest data on CM-Chitosan. Refractory osteoarthritis was at the centre of the discussions. Thank you to our twelve speakers: Pr Krik Heusdens, MD, PhD (Belgium), Dr Benoit Bouthin (France), Dr Caroline Perrin (France), Dr Bart Vundelinckx
- Le marché des injectables esthétiques pèse aujourd'hui 1,5 milliard de dollars et devrait doubler d'ici 2034. C'est dans ce contexte que s'inscrit KYTOGEN DEFEND, notre premier injectable esthétique issu de notre technologie CM-chitosan. « Kytogen Defend est certifié pour le comblement superficiel des tissus, l'amélioration de l'aspect de la peau et l'hydratation de l'épiderme au niveau du visage et du décolleté. Injecté dans le derme superficiel, il contribue à protéger l'acide hyaluronique naturellement présent dans la peau et à
- A valuable opportunity to share clinical experience, exchange perspectives, and contribute to meaningful discussions around the evolving management of knee osteoarthritis. It was a pleasure to participate in the KiOmed Clinical Expert Meeting 2026 in Brussels, sharing real-world clinical experience from Saudi Arabia alongside an international community of experts and practitioners. As a Sports Medicine and Knee consultant, I treat a wide range of knee conditions and perform both simple and complex knee surgeries, with a focus on
- What an interesting and insightful couple of days here at 4th International Clinical Expert Meeting Brussels, learning more about KioMedine CM-Chitosan and the latest clinical data on its protective effects on the synovium of the knee joint. KiOmed Pharma The discussions offered a valuable new clinical perspective on the management of refractory osteoarthritis (OA) and the potential role of CM-Chitosan in supporting joint health. Michael O'Regan, PhD It was a great pleasure to listen to my good friend and experienced KioMed user,
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.